Live Price Coverage: Celgene Corporation’s Stock Is Buy After Today’s Significant Increase

Live Price Coverage: Celgene Corporation's Stock Is Buy After Today's Significant Increase

The stock of Celgene Corporation (NASDAQ:CELG) is a huge mover today! About 1.11M shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 11.85% since April 26, 2016 and is uptrending. It has outperformed by 6.60% the S&P500.
The move comes after 6 months positive chart setup for the $94.55 billion company. It was reported on Nov, 29 by Barchart.com. We have $126.42 PT which if reached, will make NASDAQ:CELG worth $2.84 billion more.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 26. They expect $1.42 earnings per share, up 42.00% or $0.42 from last year’s $1 per share. CELG’s profit will be $1.09 billion for 21.61 P/E if the $1.42 EPS becomes a reality. After $1.39 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.16% EPS growth.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Out of 21 analysts covering Celgene Corporation (NASDAQ:CELG), 17 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 81% are positive. Celgene Corporation has been the topic of 38 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Tuesday, April 19 by Credit Suisse. Mizuho initiated Celgene Corporation (NASDAQ:CELG) rating on Tuesday, November 8. Mizuho has “Buy” rating and $130 price target. The rating was initiated by SunTrust with “Buy” on Thursday, January 7. UBS maintained the shares of CELG in a report on Friday, July 24 with “Buy” rating. Cowen & Co maintained the stock with “Outperform” rating in Wednesday, August 12 report. On Thursday, August 4 the stock rating was upgraded by BTIG Research to “Buy”. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Standpoint Research on Thursday, January 14. The company was maintained on Wednesday, October 5 by Jefferies. The firm earned “Buy” rating on Thursday, September 29 by Citigroup. The firm has “Market Perform” rating given on Friday, February 5 by Leerink Swann.

According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”

Insitutional Activity: The institutional sentiment increased to 1.11 in Q2 2016. Its up 0.12, from 0.99 in 2016Q1. The ratio increased, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
Mcrae Capital has 5.46% invested in the company for 119,630 shares. Mckinley Carter Wealth Service has 2,084 shares for 0.11% of their US portfolio. First Bancshares accumulated 0.31% or 32,176 shares. Smith Salley And Assoc reported 20,951 shares or 0.48% of all its holdings. Dupont Capital Management Corporation holds 163,008 shares or 0.36% of its portfolio. Pension Ser holds 447,656 shares or 0.39% of its portfolio. The Connecticut-based Yhb Advsr Inc has invested 1.61% in Celgene Corporation (NASDAQ:CELG). Lumina Fund Mngmt Ltd Com accumulated 0.05% or 6,000 shares. Moreover, Sumitomo Mitsui Inc has 0.42% invested in Celgene Corporation (NASDAQ:CELG) for 2.49 million shares. Nippon Life Insurance Company owns 34,290 shares or 0.08% of their US portfolio. Nj State Employees Deferred Compensation Plan last reported 0.21% of its portfolio in the stock. Reynders Mcveigh Cap has 0.09% invested in the company for 6,241 shares. The New Jersey-based Blackhill Capital has invested 0.4% in Celgene Corporation (NASDAQ:CELG). Penobscot Inv Co has 2,950 shares for 0.1% of their US portfolio. Tiverton Asset Mngmt Ltd Limited Liability Company reported 172,353 shares or 0.53% of all its holdings.

Insider Transactions: Since July 28, 2016, the stock had 0 insider buys, and 10 sales for $46.59 million net activity. $2.67 million worth of Celgene Corporation (NASDAQ:CELG) was sold by PEHL MICHAEL F. on Thursday, November 10. KAPLAN GILLA sold $1.03M worth of stock. Friedman Michael A had sold 56,116 shares worth $5.82 million on Monday, October 3. LOUGHLIN JAMES J sold $3.14M worth of stock or 27,500 shares. 100,000 shares were sold by HUGIN ROBERT J, worth $12.00M on Wednesday, November 9. MARIO ERNEST sold $1.64M worth of stock or 15,000 shares. On Monday, August 22 CASEY MICHAEL D sold $4.92 million worth of the stock or 43,134 shares.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “Better Buy: Celgene Corporation vs. Merck & Co.” on November 25, 2016, also Fool.com with their article: “Better Buy: Biogen Inc. vs. Celgene Corporation” published on November 15, 2016, Fool.com published: “3 Compelling Reasons to Buy Celgene Corporation Stock Right Now” on November 17, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Businesswire.com and their article: “Celgene Corporation to Webcast an Analyst and Investor Event from the American …” published on November 21, 2016 as well as Fool.com‘s news article titled: “Better Buy: Celgene Corporation vs. Bristol-Myers Squibb” with publication date: November 18, 2016.

CELG Company Profile

Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment